BFC
CRSP icon

Bedel Financial Consulting’s CRISPR Therapeutics CRSP Stock Holding History

Bedel Financial Consulting’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100
Closed -$4K – 821
2020
Q1 		$4K Buy
+100
New +$5.16K ﹤0.01% 599

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Bedel Financial Consulting's CRSP Position: Q2 2020 in Review

Bedel Financial Consulting sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 100 shares — an estimated $4K sold.

Bedel Financial Consulting first reported a position in CRSP in Q1 2020 and held it in 1 quarter. The position peaked at $4K in Q1 2020. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

  • Bedel Financial Consulting reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Bedel Financial Consulting sold 100 CRISPR Therapeutics shares in Q2 2020, an estimated $4K.
  • Bedel Financial Consulting first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 1 quarter.
  • Bedel Financial Consulting's CRISPR Therapeutics position peaked at $4K in Q1 2020.
  • 276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Bedel Financial Consulting's 13F filing for Q2 2020, filed 14 Jul 2020.